373 related articles for article (PubMed ID: 23221619)
41. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
[TBL] [Abstract][Full Text] [Related]
42. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of histone deacetylases class I improves adipogenic differentiation of human periodontal ligament cells.
Serralta-Interian AA; Montero Del Toro J; Nic-Can GI; Rojas-Herrera R; Aguilar-Ayala FJ; Rodas-Junco BA
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):40-47. PubMed ID: 38814236
[TBL] [Abstract][Full Text] [Related]
44. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
45. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
46. Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases.
Li Y; Li X; Guo B
Cancer Res; 2010 Jan; 70(2):646-54. PubMed ID: 20068155
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
[TBL] [Abstract][Full Text] [Related]
48. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
[TBL] [Abstract][Full Text] [Related]
49. Grape proanthocyanidins induce apoptosis by loss of mitochondrial membrane potential of human non-small cell lung cancer cells in vitro and in vivo.
Singh T; Sharma SD; Katiyar SK
PLoS One; 2011; 6(11):e27444. PubMed ID: 22087318
[TBL] [Abstract][Full Text] [Related]
50. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
51. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
Oh SH; Whang YM; Min HY; Han SH; Kang JH; Song KH; Glisson BS; Kim YH; Lee HY
Int J Cancer; 2012 Nov; 131(10):2253-63. PubMed ID: 22362554
[TBL] [Abstract][Full Text] [Related]
53. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
54. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity.
Hahm ER; Singh SV
Mol Cancer Ther; 2007 Oct; 6(10):2686-95. PubMed ID: 17938262
[TBL] [Abstract][Full Text] [Related]
55. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
56. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model.
Jiang QQ; Fan LY; Yang GL; Guo WH; Hou WL; Chen LJ; Wei YQ
BMC Cancer; 2008 Aug; 8():242. PubMed ID: 18706101
[TBL] [Abstract][Full Text] [Related]
57. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
Zhu J; Gu J; Ma J; Xu Z; Tao H
J BUON; 2015; 20(1):269-74. PubMed ID: 25778327
[TBL] [Abstract][Full Text] [Related]
58. Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway.
Chen Y; Li H; Zhang W; Qi W; Lu C; Huang H; Yang Z; Liu B; Zhang L
Toxicol Appl Pharmacol; 2020 Jan; 387():114848. PubMed ID: 31809756
[TBL] [Abstract][Full Text] [Related]
59. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and evaluation of new compounds bearing 3-(4-aminopiperidin-1-yl)methyl magnolol scaffold as anticancer agents for the treatment of non-small cell lung cancer via targeting autophagy.
Zhao M; Zheng YH; Zhao QY; Zheng W; Yang JH; Pei HY; Liu L; Liu KJ; Xue LL; Deng DX; Wang L; Ma X; Fu SH; Peng AH; Tang MH; Luo YZ; Ye HY; Chen LJ
Eur J Med Chem; 2021 Jan; 209():112922. PubMed ID: 33069436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
